Invivyd, Inc. Overview
Pro stress-test →Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company's proprietary INVYMAB platform combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering to facilitate rapid generation of new monoclonal antibodies to address evolving viral threats. In March 2024, Invivyd received FDA emergency use authorization for its first monoclonal antibody in a planned series of innovative candidates.
Strategic Profile
Pro stress-test →Invivyd is a commercial-stage company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from devastating consequences of circulating viral threats. The company is advancing VYD2311 with a Phase 3 trial (DECLARATION) targeting mid-2026 topline data and FDA Fast Track designation, while also developing an RSV candidate (VBY329) and pursuing measles monoclonal antibodies.
Competitive Landscape
Pro stress-test →One of Invivyd's 6 competitors is Vir Biotechnology, a San Francisco-based company. Invivyd competes in the monoclonal antibody space against established players including Vir, GSK, and emerging biotech firms focused on viral infectious diseases. The company's differentiation rests on its INVYMAB platform enabling rapid serial generation of variant-adapted antibodies and commercial-stage execution with PEMGARDA already generating revenue.
Industry Context
Invivyd, Inc. operates in Biopharmaceutical - Monoclonal Antibodies & Infectious Diseases.
Key facts
Founded: 2020 · Headquarters: Waltham, Massachusetts · Revenue: $17.2M · Market cap: $448M